Pfizer’s Gene Therapy Asset Chases UniQure/CSL’s Hemgenix After Pivotal Hemophilia B Success
Executive Summary
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
You may also be interested in...
Pfizer’s Growing Hematology Pipeline Matures With New Hemophilia, Sickle Cell Data
The big pharma is building on its hematology legacy beyond coagulation factors with marstacimab and gene therapies for hemophilia, plus oral and injectable medicines for sickle cell disease.
Keeping Track: First-In-Class Candidates In COPD, Cancer Join US FDA Review Queue
Recent applications for approval also include another DMD therapy, another hemophilia B gene therapy, and a new antibiotic.
Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.